biostudies-literatureUnknown14(4)Molero Senosiain MSIFI S.p.A.<h4>Introduction</h4>Dry eye disease (DED) is characterized by an imbalance in the tear film, resulting in symptoms such as dryness, redness, and discomfort. The management of DED involves tear supplements, medications, or surgery in severe cases. To evaluate the clinical performance and safety of a hypotonic ophthalmic solution containing sodium hyaluronate 0.2%, xanthan gum 0.2%, and osmoprotectants (glycine and betaine) for treating DED.<h4>Methods</h4>This multicenter, prospective, observational clinical investigation included 35 subjects treated with one drop of the ophthalmic solution four times daily. Evaluations were conducted at baseline, on day 14, and at 1 and 3 months. The investigation assessed corneal and conjunctival fluorescein staining (NEI score), hyperemia index (KeratogOphthalmology and therapy675-692https://www.ebi.ac.uk/biostudies/studies/S-EPMC11920488biostudies-literaturePerformance and Safety of a Sodium Hyaluronate, Xanthan Gum, and Osmoprotectants Ophthalmic Solution in the Treatment of Dry Eye Disease: An Observational Clinical Investigation.PMC11920488Villalba-Gonzalez MBonino LLopez Perez MDCano-Ortiz ABurgos-Blasco BVillarrubia Cuadrado ALarrosa Poves JMMateo AMolero Senosiain MPerez-Garcia PDiaz-Mesa VSanchez-Ventosa ADiaz JCArtiaga Elordi EBlasco ACiviale CfalsePerformance and Safety of a Sodium Hyaluronate, Xanthan Gum, and Osmoprotectants Ophthalmic Solution in the Treatment of Dry Eye Disease: An Observational Clinical Investigation.<h4>Introduction</h4>Dry eye disease (DED) is characterized by an imbalance in the tear film, resulting in symptoms such as dryness, redness, and discomfort. The management of DED involves tear supplements, medications, or surgery in severe cases. To evaluate the clinical performance and safety of a hypotonic ophthalmic solution containing sodium hyaluronate 0.2%, xanthan gum 0.2%, and osmoprotectants (glycine and betaine) for treating DED.<h4>Methods</h4>This multicenter, prospective, observational clinical investigation included 35 subjects treated with one drop of the ophthalmic solution four times daily. Evaluations were conducted at baseline, on day 14, and at 1 and 3 months. The investigation assessed corneal and conjunctival fluorescein staining (NEI score), hyperemia index (Keratog2025-01-01T00:00:00Z2025 Apr2026-06-02T12:00:05.496Z2025-04-03T23:26:27.044ZS-EPMC119204883998480410.1007/s40123-025-01099-x